Rate of palivizumab administration in accordance with current recommendations among hospitalized children

Journal of Pediatric Health Care

Volumn 18, Issue 5, 2004, Pages 224-227

  Moynihan, James A ^a   Kim, Tommy Y ^b   Young, Tammy ^b   Checchia, Paul A ^b  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

CHILD; CHILD HEALTH CARE; CONTROLLED STUDY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INSURANCE; MAJOR CLINICAL STUDY; RACE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRUS INFECTION;

EID: 4344580998     PISSN: 08915245     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5245(04)00064-1     Document Type: Review

References (15)

1. Alessandrini E.A., Shaw K.N., Bilker W.B., Schwarz D.F., Bell L.M. Effects of medicaid managed care on quality: Childhood immunizations. Pediatrics. 107:2001;1335-1342
2. Buckingham S.C., Quasney M.W., Bush A.J., DeVincenzo J.T. Respiratory syncytial virus infections in the pediatric intensive care unit: Clinical characteristics and risk factors for adverse outcomes. Pediatric Critical Care Medicine. 2:2001;318-323
3. Centers for Disease Control and Prevention. Respiratory syncytial virus activity - United States, 1999-2000 season. Journal of the American Medical Association. 285:2001;287-288
4. Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 102:1998;1211-1216
5. Deming L.M. Case management for pediatric respiratory syncytial virus outcomes. The Case Manager. 13:2002;72-74
6. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 102:1998;531-537
7. Leader S., Kohlhase K. RSV-coded pediatric hospitalizations and associated charges, 1997-1999. Pediatric Infectious Disease Journal. 21:2002;629-632
8. Lieu T.A., Smith M.D. Health insurance and preventive care sources of children at public immunization clinics. Pediatrics. 93:1994;373-378
9. Lindeke L.L., Krajicek M., Patterson D.L. PNP roles and interventions with children with special needs and their families. Journal of Pediatric Health Care. 15:2001;138-143
10. McManus M.A., Newacheck P. Health insurance differentials among minority children with chronic conditions and the role of federal agencies and private foundations in improving financial access. Pediatrics. 91:1993;1040-1047
11. Meissner H.C., Welliver R.C., Chartrand S.A., Law B.J., Weisman L.E., Dorkin H.L., et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high-risk infants: A consensus opinion. Pediatric Infectious Disease Journal. 18:1999;223-231
12. Newacheck P.W., Halfon N. Access to ambulatory care services for economically disadvantaged children. Pediatrics. 78:1986;813-819
13. Newacheck P.W., Stoddard J.J., McManus M. Ethnocultural variations in the prevalence and impact of childhood chronic conditions. Pediatrics. 91:1993;1031-1039
14. Shay D.K., Holman R.C., Newman R.D., Liu L.L., Stout J.W., Anderson L.J. Bronchiolitis-associated hospitalizations among U.S. children, 1980-1996. Journal of the American Medical Association. 282:1999;1440-1446
15. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. Journal of the American Medical Association. 289:2003;2499-2503